Skip to Main Content

Paper Details

Rituximab as therapy for the recurrence of bile salt export pump deficiency after liver transplantation.
Liver Transpl
24
2013
BSEP, BSEP disease, PFIC2, Progressive familial intrahepatic cholestasis type 2, Rituximab, adenosine triphosphate, adenosine triphosphate-binding cassette B11 gene, allograft rejection, anti-BSEP antibodies, bile salt, bile salt export pump deficiency, chimeric monoclonal anti-CD20 antibody, cholestasis, cholestatic graft dysfunction, end-stage liver disease, immunoglobulin, immunoglobulin G antibodies, patients, rituximab

Datasets

Release 1.2